Sept 3, 2024 - LONDON & NEW YORK - Huma Therapeutics (“Huma”), a leading global healthcare AI company, today announced a partnership with Servier Pharmaceuticals to launch an innovative patient support app for individuals diagnosed with glioma, a type of tumour originating in the glial cells of the brain or spinal cord.
Adult type diffuse gliomas are the most common type of primary central nervous (CNS) system tumor, accounting for 79% of all CNS tumors, and can be diagnosed at any age. Depending on the location, size and grade of the tumor, symptoms and prognosis may vary widely, potentially including cognitive and behavioural impacts or motor deficits. Beyond the physical effects of glioma, patients and caregivers often experience significant emotional distress in navigating a complicated treatment pathway.
The Glioma app is a resource for patients, providing access to clinically validated information about their condition and treatment options, as well as tools to help them. Features include:
- Educational resources and information on glioma
- Medication reminders
- Symptom tracking
The service will be freely available to all patients in the United States, with potential for additional launches in multiple countries in the future. Huma and Servier intend to continually enhance the app with input from users. The application is available for download at this link, or can be accessed by scanning the QR code.
“Supporting people living with cancer has been a priority at Huma since day one. We are proud to be working with Servier to help glioma patients get access to critical information about their condition and monitor their disease,” said Huma CEO Dan Vahdat.
“At Servier, our unique governance allows us to focus on patient centricity across all aspects of our organization,” said Wendy Poage, Vice President of Servier’s Patient Office. “We are consistently working to identify the complexities and challenges that patients and caregivers experience and aim to find solutions. This app is one example of the ‘beyond the pill’ digital solutions we are working to provide to patients, caregivers, advocacy groups and others.”
About Huma
Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research.
Huma’s technology has powered over 3,000 hospitals and clinics. The platform has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products in 70+ countries. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as collaborating with most large pharma companies and CROs.
The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, Saudi FDA Class C, and India CDSCO Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.
Please visit www.huma.com and follow us on LinkedIn at Huma.
